Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer - PubMed (original) (raw)

Clinical Trial

. 2005 Nov-Dec;28(6):593-8.

doi: 10.1097/01.cji.0000178913.41256.06.

Kimberly E Beck, Khoi Tran, James C Yang, Marybeth S Hughes, Udai S Kammula, Richard E Royal, Suzanne L Topalian, Leah R Haworth, Catherine Levy, Steven A Rosenberg, Richard M Sherry

Affiliations

• PMID: 16224277
• PMCID: PMC2154350
• DOI: 10.1097/01.cji.0000178913.41256.06

Clinical Trial

Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer

Joseph A Blansfield et al. J Immunother. 2005 Nov-Dec.

Abstract

Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) is an immunoregulatory molecule expressed by activated T cells and resting CD4CD25 T cells. In patients with advanced melanoma, our group reported that administration of anti-CTLA-4 antibody mediated objective cancer regression in 13% of patients. This study also established that the blockade of CTLA-4 was associated with grade III/IV autoimmune manifestations that included dermatitis, enterocolitis, hepatitis, uveitis, and a single case of hypophysitis. Since this initial report, 7 additional patients with anti-CTLA-4 antibody-induced autoimmune hypophysitis have been accumulated. The characteristics, clinical course, laboratory values, radiographic findings, and treatment of these 8 patients are the focus of this report.

PubMed Disclaimer

Figures

FIGURE 1

Sagittal MRI section from patient 7 before anti-CTLA-4 antibody treatment and at various intervals during treatment, including the time of clinical symptom onset. Pituitary height is in parentheses.

Similar articles

• Anti-CTLA-4 therapy-related autoimmune hypophysitis in a melanoma patient.
  Kaehler KC, Egberts F, Lorigan P, Hauschild A. Kaehler KC, et al. Melanoma Res. 2009 Oct;19(5):333-4. doi: 10.1097/CMR.0b013e32832e0bff. Melanoma Res. 2009. PMID: 19512947
• Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma.
  Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth LR, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, Duray PH, Steinberg SM, Allison JP, Davis TA, Rosenberg SA. Phan GQ, et al. Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8372-7. doi: 10.1073/pnas.1533209100. Epub 2003 Jun 25. Proc Natl Acad Sci U S A. 2003. PMID: 12826605 Free PMC article. Clinical Trial.
• Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4.
  Beck KE, Blansfield JA, Tran KQ, Feldman AL, Hughes MS, Royal RE, Kammula US, Topalian SL, Sherry RM, Kleiner D, Quezado M, Lowy I, Yellin M, Rosenberg SA, Yang JC. Beck KE, et al. J Clin Oncol. 2006 May 20;24(15):2283-9. doi: 10.1200/JCO.2005.04.5716. J Clin Oncol. 2006. PMID: 16710025 Free PMC article.
• CTLA-4 blockade with monoclonal antibodies in patients with metastatic cancer: surgical issues.
  Phan GQ, Weber JS, Sondak VK. Phan GQ, et al. Ann Surg Oncol. 2008 Nov;15(11):3014-21. doi: 10.1245/s10434-008-0104-y. Epub 2008 Aug 21. Ann Surg Oncol. 2008. PMID: 18716842 Review.
• Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes.
  Dillard T, Yedinak CG, Alumkal J, Fleseriu M. Dillard T, et al. Pituitary. 2010;13(1):29-38. doi: 10.1007/s11102-009-0193-z. Epub 2009 Jul 29. Pituitary. 2010. PMID: 19639414 Review.

Cited by

• Molecular Pathways: Breaking the Epithelial Cancer Barrier for Chimeric Antigen Receptor and T-cell Receptor Gene Therapy.
  Hinrichs CS. Hinrichs CS. Clin Cancer Res. 2016 Apr 1;22(7):1559-64. doi: 10.1158/1078-0432.CCR-15-1294. Clin Cancer Res. 2016. PMID: 27037253 Free PMC article. Review.
• The role of tregs in glioma-mediated immunosuppression: potential target for intervention.
  Humphries W, Wei J, Sampson JH, Heimberger AB. Humphries W, et al. Neurosurg Clin N Am. 2010 Jan;21(1):125-37. doi: 10.1016/j.nec.2009.08.012. Neurosurg Clin N Am. 2010. PMID: 19944972 Free PMC article. Review.
• Immune Checkpoint Inhibitor Toxicity.
  Palmieri DJ, Carlino MS. Palmieri DJ, et al. Curr Oncol Rep. 2018 Jul 31;20(9):72. doi: 10.1007/s11912-018-0718-6. Curr Oncol Rep. 2018. PMID: 30066230 Review.
• Immunotherapy for metastatic prostate cancer.
  Drake CG. Drake CG. Urol Oncol. 2008 Jul-Aug;26(4):438-44. doi: 10.1016/j.urolonc.2007.03.029. Epub 2007 Dec 21. Urol Oncol. 2008. PMID: 18593624 Free PMC article. Review.
• Neurotoxicity of Tumor Immunotherapy: The Emergence of Clinical Attention.
  Zhang B, Li X, Yin T, Qin D, Chen Y, Ma Q, Shu P, Wang Y. Zhang B, et al. J Oncol. 2022 Jan 18;2022:4259205. doi: 10.1155/2022/4259205. eCollection 2022. J Oncol. 2022. PMID: 35087588 Free PMC article. Review.

References

1. 1. Attia P, Phan GQ, Maker AV, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-CTLA-4. J Clin Oncol. In press. - PMC - PubMed
2. 1. Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA. 2003;100:8372–8377. - PMC - PubMed
3. 1. Goudie EB, Pinkerton PH. Anterior hypophysitis and Hashimoto's disease in a young woman. J Pathol Bacteriol. 1962;83:584–585. - PubMed
4. 1. Thoudou E, Asa S, Kontogeorgos G, et al. Clinical case seminar: lymphocytic hypophysitis: clinicopathological findings. J Clin Endocrinol Metab. 1995;80:2302–2311. - PubMed
5. 1. Abe T, Matsumoto K, Sanno N, et al. Lymphocytic hypophysitis: case report. Neurosurgery. 1995;36:1016–1019. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • Ovid Technologies, Inc.
  • PubMed Central
  • Wolters Kluwer

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information